Front Row Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Front Row Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18	Closed	-$4.92K	–	542
2024 Q2	$4.92K	Sell	18 -2	-10%	-$582	﹤0.01%	731
2024 Q1	$6.92K	Buy	+20	New	+$6.58K	﹤0.01%	667
2023 Q4	–	Sell	-17	Closed	-$6.09K	–	514
2023 Q3	$6.09K	Hold	17	–	–	﹤0.01%	627
2023 Q2	$6K	Buy	17 +4	+31%	+$1.63K	﹤0.01%	624
2023 Q1	$6K	Sell	13 -1	-7%	-$468	﹤0.01%	627
2022 Q4	$6K	Buy	14 +5	+56%	+$2.02K	﹤0.01%	594
2022 Q3	$4K	Hold	9	–	–	﹤0.01%	680
2022 Q2	$4K	Buy	9 +1	+13%	+$521	﹤0.01%	704
2022 Q1	$5K	Sell	8 -4	-33%	-$2.41K	﹤0.01%	709
2021 Q4	$9K	Sell	12 -2	-14%	-$1.5K	﹤0.01%	594
2021 Q3	$10K	Hold	14	–	–	﹤0.01%	558
2021 Q2	$11K	Hold	14	–	–	﹤0.01%	532
2021 Q1	$8K	Buy	14 +1	+8%	+$592	﹤0.01%	593
2020 Q4	$8K	Hold	13	–	–	﹤0.01%	561
2020 Q3	$7K	Sell	13 -4	-24%	-$2.03K	﹤0.01%	585
2020 Q2	$8K	Hold	17	–	–	0.01%	513
2020 Q1	$7K	Sell	17 -2	-11%	-$735	﹤0.01%	533
2019 Q4	$7K	Hold	19	–	–	﹤0.01%	531
2019 Q3	$6K	Buy	19 +4	+27%	+$1.3K	﹤0.01%	547
2019 Q2	$5K	Hold	15	–	–	﹤0.01%	568
2019 Q1	$5K	Hold	15	–	–	﹤0.01%	569
2018 Q4	$3K	Hold	15	–	–	﹤0.01%	654
2018 Q3	$4K	Buy	+15	New	+$4.66K	﹤0.01%	592

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Front Row Advisors's BIO Position: Q3 2024 in Review

Front Row Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 18 shares — an estimated $4.92K sold.

Front Row Advisors first reported a position in BIO in Q3 2018 and held it in 23 quarters. The position peaked at $11K in Q2 2021. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Front Row Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Front Row Advisors sold 18 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $4.92K.
Front Row Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 23 quarters.
Front Row Advisors's Bio-Rad Laboratories Class A position peaked at $11K in Q2 2021.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.